Table 1. Summary of scientific studies included in the editorial describing clinical-pathological features of STAS-positive lung adenocarcinomas.
| Study | Resected ADC | STAS- positive ADC (%) | Male sex (%) | Positive smoking history (%)a | Tumor size (mm) | Pathological stage | Limited surgical resection (%)b | Survival and recurrence (%) |
|---|---|---|---|---|---|---|---|---|
| Kadota (2) | 411 | 155 (38%) | 36.1 | 88.3 | ≤20 | I | 30 | 42.6 (5-year CIR)d
59.3 (5-year OS)d |
| Shiono (3) | 318 | 47 (15%) | 70.2 | 72.3 | 21 (median tumor size) | I | 32 | 62.7 (5-year OS) 54.4 (5-year RFS) |
| Toyokawa (4) | 327 | 191 (58%) | 48.2 | 49.2 | ≥20 (53.9%) | I (70.4%) ≥ II (29.6%) | 16.8 | 42.9 (5-year OS) 31.9 (5-year RFS) |
| Kim (5) | 276 | 92 (33%) | 46.7 | 40.2 | 29.6±20.4g (max tumor diameter) | – | 3.3 | 86 (12-month RFS) |
| de Margerie-Mellon (6) | 80 | 40 (50%) | 40 | 75 | 20.47±6.01g (max tumor diameter) | – | – | – |
| Hu (25) | 500 | 134 (27%) | 45.5 | 25.3 | 25±1.4g (max tumor diameter) | I (76.9%) ≥ II (23.1%) | – | – |
| Warth (26) | 569 | 288 (51%) | 65.6 | 44.7 | – | I (32.6%) ≥ II (67.4%) | 3.1 (of all patients) | ~48 (5-year OS) 44.6 (5-year DFS) |
a, including past and current smoking history; b, including wedge resection and segmentectomy; d, considering STAS-positive ADC treated with limited resection only; g, mean ± standard deviation. STAS, spread through air spaces; ADC, adenocarcinoma; CIR, cumulative incidence of recurrence; DFS, disease free survival; OS, overall survival; RFS, recurrence free survival.